EGFR and mesothelioma: A number of selective inhibitors of the TEAD family members are in development and have been shown to disrupt YAP1/WWTR1/TEAD-dependent transcription, affect the viability of NF2 mutant mesothelioma models, and to enhance the efficacy of EGFR inhibitors in EGFR mutant lung cancer5,16,22.